<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01128400</url>
  </required_header>
  <id_info>
    <org_study_id>09-0873</org_study_id>
    <nct_id>NCT01128400</nct_id>
  </id_info>
  <brief_title>Fat Perception in Humans (09-0873)</brief_title>
  <acronym>OT</acronym>
  <official_title>Inhibition of Lipolysis in Oral Cavity and Fat Perception in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are many substances naturally present in the mouth that may help us taste fat in food.
      Two of these substances (lipases and CD36) will be examined in this study.

      The presence of fat in food increases food tastiness, therefore people often over-eat
      high-fat foods and gain weight. The purpose of this study is to determine if blocking lipases
      and some genetic variations in the CD36 gene will make fatty food less tasty so that people
      eat less. Our hypothesis is that Orlistat and a particular gene will increase one's ability
      to detect fat.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Determine the effect of lipolysis inhibition in oral cavity on orosensory detection of
           fat in humans.

           Hypothesis: Orally applied Orlistat will increase detection thresholds of TAGs but not
           FFA in humans.

           To test this hypothesis we will measure triolein (a TAG) and oleic acid (a FFA) taste
           detection thresholds with a three-alternative forced-choice (3-AFC) ascending
           concentration method under two conditions (Orlistat day vs. Control day). To control for
           olfactory input, subjects will be assessed wearing noseclips.

        2. Determine the effect of CD36 variants on fat taste perception in humans. Hypothesis:
           SNPs that associate with reduced CD36 expression will be associated with higher FFA and
           TAG detection thresholds

      To test this hypothesis we will measure triolein and oleic acid taste detection thresholds in
      subjects who carry of the common CD36 e-SNP rs1761667 (i.e. a SNP that significantly reduces
      CD36 level and has a minor allele frequency of 38-48%). We expect subjects who are at least
      heterozygous for the expression reducing allele to have higher triolein and oleic acid taste
      detection thresholds compared to non-carrier subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Oleic Acid Detection Level</measure>
    <time_frame>Few weeks after screening</time_frame>
    <description>We will measure oleic acid detection levels as a marker of subjects' ability to detect free fatty acids.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triolein Detection</measure>
    <time_frame>Few weeks after screening</time_frame>
    <description>We will measure triolein detection levels as a marker of subjects' ability to detect triglyceride.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>rs1761667- AA genotype</arm_group_label>
    <description>subjects carrying the CD36 genotype rs1761667, i.e. a Single Nucleotide Polymorphism that significantly reduces CD36 level and has a minor allele frequency of 38-48%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rs1761667-GG genotype</arm_group_label>
    <description>subjects who are homozygous of CD36 genotype rs1761667-G allele.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rs1761667-AG genotype</arm_group_label>
    <description>Heterozygous of CD36 gene rs1761667-A genotype.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood will be collected and frozen
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 40 obese subjects will participate in this study. Subjects will be men and women
        and will include all races and ethnic groups. The two groups (carriers and non-will be
        matched as closely as possible in age, sex, body mass index (kg/m2) and race distributions.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index greater than 30 kg/m2

        Exclusion Criteria:

          -  smokers or who quit smoking less than six months ago

          -  pregnancy

          -  breastfeeding

          -  diabetes

          -  taking medications that might affect taste perception

          -  previous malabsorptive or restrictive intestinal surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Y Pepino de Gruev, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>May 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2010</study_first_posted>
  <results_first_submitted>June 2, 2014</results_first_submitted>
  <results_first_submitted_qc>June 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 3, 2014</results_first_posted>
  <last_update_submitted>June 2, 2014</last_update_submitted>
  <last_update_submitted_qc>June 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Marta Yanina Pepino de Gruev</investigator_full_name>
    <investigator_title>Research Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>orlistat</keyword>
  <keyword>taste perception</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>May 2010- August 2011 recruited by local posters and media advertising via the Washington University Research Participant Registry.</recruitment_details>
      <pre_assignment_details>40 subjects signed consent form and were screened for rs1761667 genotype and three groups (i.e., AA, AG and GG) matched in age and BMI were invited to participate on the taste test.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>rs1761667- AA Genotype</title>
          <description>subjects carrying the CD36 genotype rs1761667, i.e. a Single Nucleotide Polymorphism that significantly reduces CD36 level and has a minor allele frequency of 38-48%.</description>
        </group>
        <group group_id="P2">
          <title>rs1761667-GG Genotype</title>
          <description>subjects who are homozygous of CD36 genotype rs1761667-G allele.</description>
        </group>
        <group group_id="P3">
          <title>rs1761667-AG Genotype</title>
          <description>Heterozygous of CD36 gene rs1761667-A genotype.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screening failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>were not invited to participate on taste</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Three groups of obese subjects (body mass index [BMI] &gt;30 kg/m2) participated in this study. The three groups were matched on age, because there is a generic decline in taste perception with age.</population>
      <group_list>
        <group group_id="B1">
          <title>rs1761667- AA Genotype</title>
          <description>Obese subjects carrying the CD36 genotype rs1761667, i.e. a Single Nucleotide Polymorphism that significantly reduces CD36 level</description>
        </group>
        <group group_id="B2">
          <title>rs1761667-GG Genotype</title>
          <description>Obese subjects who are homozygous of CD36 genotype rs1761667-G allele.</description>
        </group>
        <group group_id="B3">
          <title>rs1761667-AG Genotype</title>
          <description>Obese subjects who are heterozygous of CD36 gene rs1761667-A genotype.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.7" spread="14.0"/>
                    <measurement group_id="B2" value="39.1" spread="7.0"/>
                    <measurement group_id="B3" value="39.6" spread="6.4"/>
                    <measurement group_id="B4" value="39.1" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Oleic Acid Detection Level</title>
        <description>We will measure oleic acid detection levels as a marker of subjects' ability to detect free fatty acids.</description>
        <time_frame>Few weeks after screening</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rs1761667- AA Genotype</title>
            <description>Obese subjects carrying the CD36 genotype rs1761667, i.e. a Single Nucleotide Polymorphism that significantly reduces CD36 level</description>
          </group>
          <group group_id="O2">
            <title>rs1761667-GG Genotype</title>
            <description>Obese subjects who are homozygous of CD36 genotype rs1761667-G allele.</description>
          </group>
          <group group_id="O3">
            <title>rs1761667-AG Genotype</title>
            <description>Obese subjects who are heterozygous of CD36 gene rs1761667-A genotype.</description>
          </group>
        </group_list>
        <measure>
          <title>Oleic Acid Detection Level</title>
          <description>We will measure oleic acid detection levels as a marker of subjects' ability to detect free fatty acids.</description>
          <units>log10 (%W/V OLEIC ACID)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.3"/>
                    <measurement group_id="O2" value="-1.2" spread="0.2"/>
                    <measurement group_id="O3" value="-1.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Triolein Detection</title>
        <description>We will measure triolein detection levels as a marker of subjects' ability to detect triglyceride.</description>
        <time_frame>Few weeks after screening</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rs1761667- AA Genotype</title>
            <description>Obese subjects carrying the CD36 genotype rs1761667, i.e. a Single Nucleotide Polymorphism that significantly reduces CD36 level</description>
          </group>
          <group group_id="O2">
            <title>rs1761667-GG Genotype</title>
            <description>Obese subjects who are homozygous of CD36 genotype rs1761667-G allele.</description>
          </group>
          <group group_id="O3">
            <title>rs1761667-AG Genotype</title>
            <description>Obese subjects who are heterozygous of CD36 gene rs1761667-A genotype.</description>
          </group>
        </group_list>
        <measure>
          <title>Triolein Detection</title>
          <description>We will measure triolein detection levels as a marker of subjects' ability to detect triglyceride.</description>
          <units>log10 (%W/V TRIOLEIN)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.25"/>
                    <measurement group_id="O2" value="-0.33" spread="0.22"/>
                    <measurement group_id="O3" value="-0.04" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>rs1761667- AA Genotype</title>
          <description>Obese subjects carrying the CD36 genotype rs1761667, i.e. a Single Nucleotide Polymorphism that significantly reduces CD36 level</description>
        </group>
        <group group_id="E2">
          <title>rs1761667-GG Genotype</title>
          <description>Obese subjects who are homozygous of CD36 genotype rs1761667-G allele.</description>
        </group>
        <group group_id="E3">
          <title>rs1761667-AG Genotype</title>
          <description>Obese subjects who are heterozygous of CD36 gene rs1761667-A genotype.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>M. Yanina Pepino</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>3143628113</phone>
      <email>ypepino@dom.wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

